Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.50 |
| ▸ | GGT1 | P19440 | 2/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39093 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL148584 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL4303994 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Glycine SCHEMBL10994359 | 0.89 | SLC7A5 (0.52) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Aspartic Acid SCHEMBL22557639 | 0.89 | SLC7A5 (0.52) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL6827952 | 0.89 | SLC1A1 (0.60) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Alanine SCHEMBL10991017 | 0.89 | SLC7A5 (0.65) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL600881 | 0.87 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL9545322 | 0.87 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL29024969 | 0.87 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064075-A1 | CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE | INSPIRATION BIOPHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| EP-1432794-B1 | HUMAN COAGULATION FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| WO-2011092242-A1 | FACTOR VII FUSION POLYPEPTIDES | NOVO NORDISK HEALTH CARE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| EP-2316930-A1 | Human coagulation factor VII polypeptides | Novo Nordisk Health Care AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20110040073-A1 | Covalent Factor VII-Tissue Factor Complex | NOVO NORDISK HEALTHCARE A/G (CH) | 2011-02-17 | — | — | US | disclosed |
| US-6235707-B1 | Anticoagulant peptidyl-arginine aldehyde derivatives | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040073-A1 | Covalent Factor VII-Tissue Factor Complex | F13B, F7, HABP2 | SLC7A5 3724/4885SLC1A1 4667/4885SLC1A3 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.